Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA) has granted inducement awards to ten new employees under its 2024 Inducement Plan. The grants include 73,459 restricted stock units (RSUs) of common stock, which will vest in three equal installments on November 1, 2025, 2026, and 2027. These awards were granted outside the company's stockholder-approved equity incentive plans and were approved by Intellia's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) ha concesso premi di induzione a dieci nuovi dipendenti nell'ambito del suo Piano di Induzione 2024. I premi includono 73.459 unità azionarie vincolate (RSU) di azioni ordinarie, che saranno maturate in tre rate uguali il 1° novembre 2025, 2026 e 2027. Questi premi sono stati concessi al di fuori dei piani di incentivazione azionaria approvati dagli azionisti dell'azienda e sono stati approvati dal comitato di compensazione di Intellia in conformità con la Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) ha otorgado premios de inducción a diez nuevos empleados bajo su Plan de Inducción 2024. Los premios incluyen 73,459 unidades de acciones restringidas (RSUs) de acciones comunes, que se otorgarán en tres cuotas iguales el 1 de noviembre de 2025, 2026 y 2027. Estos premios se concedieron fuera de los planes de incentivos de capital aprobados por los accionistas de la compañía y fueron aprobados por el comité de compensación de Intellia de acuerdo con la Regla de Listado de Nasdaq 5635(c)(4).
인텔리아 테라퓨틱스(NASDAQ:NTLA)는 2024 유인 계획에 따라 10명의 신규 직원에게 유인 보상을 부여했습니다. 이 보상에는 73,459개의 제한된 주식 단위(RSU)가 포함되어 있으며, 이는 2025년, 2026년, 2027년 11월 1일에 세 번의 동등한 할당으로 행사됩니다. 이 보상은 회사 주주가 승인한 주식 인센티브 계획 외부에서 부여되었으며, 나스닥 상장 규칙 5635(c)(4)에 따라 인텔리아의 보상 위원회에서 승인되었습니다.
Intellia Therapeutics (NASDAQ:NTLA) a accordé des primes d'incitation à dix nouveaux employés dans le cadre de son Plan d'incitation 2024. Les primes comprennent 73 459 unités d'actions restreintes (RSU) d'actions ordinaires, qui seront acquises en trois versements égaux le 1er novembre 2025, 2026 et 2027. Ces primes ont été accordées en dehors des plans d'incitation en actions approuvés par les actionnaires de l'entreprise et ont été approuvées par le comité de rémunération d'Intellia conformément à la règle de cotation Nasdaq 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA) hat im Rahmen seines Induktionsplans 2024 zehn neuen Mitarbeitern Anreizvergütungen gewährt. Die Vergaben umfassen 73.459 beschränkt übertragbare Aktieneinheiten (RSUs), die in drei gleichen Raten am 1. November 2025, 2026 und 2027 fällig werden. Diese Vergaben wurden außerhalb der von den Aktionären des Unternehmens genehmigten Aktienanreizpläne gewährt und wurden vom Vergütungsausschuss von Intellia gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- None.
- Potential shareholder dilution from issuance of 73,459 new shares through RSUs
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on November 1, 2024 it awarded inducement grants to ten new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grants consisted of time-based restricted stock units (“RSUs”) for 73,459 shares of Intellia’s common stock, with one-third of such RSUs vesting on November 1, 2025, 2026, and 2027.
All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. The awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company’s in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Lina Li
Senior Director, Investor Relations and Corporate Communications
lina.li@intelliatx.com
FAQ
How many RSUs did Intellia Therapeutics (NTLA) grant in its November 2024 inducement awards?
What is the vesting schedule for Intellia Therapeutics' (NTLA) November 2024 inducement RSUs?
Under which plan did Intellia Therapeutics (NTLA) issue its November 2024 inducement grants?
